IPSEN (OTCMKTS:IPSEY) Sees Large Volume Increase – Time to Buy?

IPSEN (OTCMKTS:IPSEY – Get Free Report) saw strong trading volume on Monday . 5,114 shares traded hands during trading, an increase of 134% from the previous session’s volume of 2,190 shares.The stock last traded at $48.13 and had previously closed at $46.50.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IPSEY. Zacks Research raised IPSEN to a “hold” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, IPSEN currently has a consensus rating of “Hold”.

Get IPSEN alerts:

Check Out Our Latest Report on IPSEY

IPSEN Price Performance

The business’s 50 day simple moving average is $47.13 and its 200 day simple moving average is $44.28.

About IPSEN

(Get Free Report)

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).

Read More

• Five stocks we like better than IPSEN
• Apple and Broadcom Forge a Decade-Long Silicon Fortress
• SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
• The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
• Palantir’s CEO Just Called Out OpenAI and Anthropic

Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.